Louisiana State Employees Retirement System Buys Shares of 30,100 QuidelOrtho Corporation $QDEL

Louisiana State Employees Retirement System bought a new position in shares of QuidelOrtho Corporation (NASDAQ:QDEL) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 30,100 shares of the company’s stock, valued at approximately $495,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Global Retirement Partners LLC increased its position in QuidelOrtho by 3,691.7% in the 4th quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after acquiring an additional 886 shares during the period. Camelot Portfolios LLC bought a new position in shares of QuidelOrtho during the fourth quarter valued at $29,000. Hantz Financial Services Inc. lifted its holdings in shares of QuidelOrtho by 50.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after purchasing an additional 362 shares during the period. Larson Financial Group LLC lifted its holdings in shares of QuidelOrtho by 322.2% during the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock worth $39,000 after purchasing an additional 1,015 shares during the period. Finally, EverSource Wealth Advisors LLC grew its stake in shares of QuidelOrtho by 250.7% in the second quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock worth $93,000 after purchasing an additional 2,309 shares during the last quarter. 99.00% of the stock is owned by institutional investors.

QuidelOrtho Price Performance

Shares of NASDAQ QDEL opened at $17.25 on Thursday. QuidelOrtho Corporation has a twelve month low of $9.92 and a twelve month high of $35.58. The firm has a fifty day simple moving average of $13.40 and a 200 day simple moving average of $19.64. The company has a market capitalization of $1.18 billion, a PE ratio of -0.97 and a beta of 0.69. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33.

QuidelOrtho (NASDAQ:QDEL) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The firm had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The business’s revenue was down 10.5% compared to the same quarter last year. During the same period last year, the company posted $0.74 EPS. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, sell-side analysts forecast that QuidelOrtho Corporation will post 1.87 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on QDEL shares. Citigroup raised their target price on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research report on Wednesday. JPMorgan Chase & Co. increased their price target on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research note on Wednesday, July 1st. UBS Group restated a “neutral” rating and set a $12.00 price objective on shares of QuidelOrtho in a research report on Thursday, May 7th. Jefferies Financial Group reaffirmed a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a report on Tuesday, April 21st. Four analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, QuidelOrtho presently has a consensus rating of “Reduce” and an average price target of $13.62.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.